Finally, results from the Canadian Multicentre Osteoporosis Study (CaMos) showed that sclerostin levels are associated with fasting insulin levels and HOMA-IR, but not with the risk of incident T2DM (52). This evidence concerns the gene INS and type 2 diabetes mellitus.